Unsuccessful in licensing talks, feds sue Gilead over PrEP-focused HIV patent
Gilead Sciences balked at licensing the U.S. government's HIV-prevention patent rights, and now the feds are striking back.
The Department of Health and Human Services sued Gilead for patent infringement Wednesday, saying the company and its HIV prophylaxis meds Truvada and Descovy reaped profits off hundreds of millions of dollars in taxpayer-funded research.
The patent dust-up comes as Gilead's original HIV-prevention drug Truvada nears the end of its patent life and its successor, Descovy, is working to take its place. Descovy won its FDA nod for HIV prophylaxis earlier this year, and company executives have been talking up efforts to move business to the newer med.